我們已在上線!
進一步了解
Lite Strategy Inc
LITS
LITS
關於: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
員工: 5
新聞
正面
中性
負面
市場情緒
3個月
正面
0%
中性
100%
負面
0%
價格圖表採用Lightweight Charts™實作